Carl Grove
Comentis, Inc. · CoMentis (formerly Athenagen) · CoMentis
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Carl Grove as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:43 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT00607750 · Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGFCoMentis · completed · Age-Related Macular Degeneration · study director
- Ph1/Ph2NCT00419445 · Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity DisorderCoMentis · completed · Attention Deficit Hyperactivity Disorder · study director
- Ph2NCT00414206 · Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)CoMentis · terminated · Macular Degeneration · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:43 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:43 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).J Clin Oncol · 2025236 citationsRCR 60.4
- 79 citationsRCR 18.7
- Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.Blood · 201652 citationsRCR 1.5
- Novel gaze stability training improves dynamic visual acuity for 6 months.J Vestib Res · 20260 citationsRCR 0.0